Why are KOLs encouraged by trial results of Astellas/Ganymed's pipeline anti-claudin 18.2 mAb zolbetuximab and in what settings do they see it delivering value? What safety concerns do experts express that could limit the first-line prospects of AstraZeneca/Daiichi Sankyo's Enhertu? Could Zymeworks' IgG1 bi-specific mAb Zanidatamab displace trastuzumab/pembrolizumab/chemotherapy? KOLs critically assess the prospects of launched and pipeline therapies.
Table of Contents
Executive summary
Current and future treatment algorithm
Research objectives
Marketed treatments
- Chemotherapy regimens and current treatment trends
- Herceptin (trastuzumab; Roche)
- Enhertu (trastuzumab deruxtecan; AstraZeneca/Daiichi Sankyo)
- Cyramza (ramucirumab; Lilly)
- Key insights summary
- Keytruda (pembrolizumab; Merck & Co.)
- Nivolumab (Opdivo; BMS/Ono)
Late-stage pipeline programmes
- Immunotherapies
- Durvalumab (Imfinzi; AstraZeneca)
- Sintilimab (Tyvyt; Innovent Biologics/ Lilly)
- Tislelizumab (BGB-A317; BeiGene/Novartis)
- Avelumab (Bavencio; Merck Group/Pfizer)
- Atezolizumab (Tecentriq; Roche)
- Targeted biologic therapies
- Zolbetuximab (IMAB362/claudiximab; Astellas/Ganymed)
- Margetuximab/retifanlimab/tebotelimab (MacroGenics/Incyte)
- Bemarituzumab (Five Prime Therapeutics/Amgen)
- Zanidatamab (ZW25; Zymeworks)
- Evorpacept (ALX Oncology)
- Catumaxomab (Removab; LintonPharm)
- ARX788 (Ambrx/Zhejiang Medicine)
- Targeted oral therapies
- Stivarga (regorafenib; Bayer)
- PARP inhibitors
- Olaparib (Lynparza; AstraZeneca); pamiparib (BeiGene)
- Next-generation therapies
- Sirexatamab (DKN-01; Leap Therapeutics/BeiGene)
Future treatment trends
- Cell therapies and gastric cancer vaccines
- Other promising pipeline technologies for gastric cancer
Appendix
- KOL details
- KOLs from the USA
- KOLs from Europe